Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes

Gærtner, S.; Cordeanu, Elena-Mihaela; Nouri, Saeed; Faller, Alix-Marie; Frantz, A.-S.; Mirea, C.; Bilbault, Pascal; Ohlmann, Patrick; Ray, Isabelle Le; Stephan, Dominique

doi:10.1016/j.ijcard.2016.10.045

Cited by 44 publications

(61 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The REMOTEV cohort included 499 patients with DVT and PE. 49 The rates of major bleeding, and recurrent DVT with rivaroxaban were coherent with those reported in XALIA registry, 1.4 versus 3.1%, respectively. The frequency of major bleeding was 1.1% in rivaroxaban group versus 3.1% in the warfarin group.…”

Section: Real-life Registriessupporting

confidence: 83%

See 1 more Smart Citation

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Tromeur

Pol

Mairuhu

et al. 2018

Semin intervent Radiol

View full text Add to dashboard Cite

Anticoagulant therapy is the cornerstone of therapeutic management in acute venous thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis. Direct oral anticoagulants (DOACs) have become the standard of care because of their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs provided a similar efficacy and a better safety than conventional treatment with parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE therapeutic management. The results of published data from real-world registries confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.

show abstract

Section: Real-life Registriessupporting

confidence: 83%

“…We will discuss the largest studies published to date. [46][47][48][49][50] The results of these noninterventional studies are summarized in ►Table 4.…”

Section: Real-life Registriesmentioning

confidence: 99%

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Tromeur

Pol

Mairuhu

et al. 2018

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…These studies reported rates of major bleeding which vary between 0.5 and 4% (►Table 5). 5,6,[21][22][23][24][25][26][27] Higher rates of major bleeding (4.1% per annum) were observed in the Dresden registry 21 compared with the XALIA (XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in venous thromboembolism) study, 25 which had lower rates of bleeding (1.2% per annum). This difference is partly explained by younger patients in the XALIA study (74 vs. 59 years) and a lower proportion with impaired renal function (11 vs. 4% had glomerular filtration rate or CrCl < 50 mL/min).…”

Section: Rates Of Bleeding and Vte Recurrencementioning

confidence: 99%

Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study

Lim

Indran

Cummins

et al. 2018

Semin Thromb Hemost

View full text Add to dashboard Cite

The highest risk of adverse events for patients with acute venous thromboembolism (VTE) is during the early anticoagulation period. However, no established model exists for early clinical monitoring of patients treated with non–vitamin K antagonist oral anticoagulants (NOACs). The authors' aim was to evaluate the utility of a nurse-led pathway to minimize adverse events in acute VTE patients starting on rivaroxaban. The rivaroxaban VTE treatment pathway is a prospective cohort study of consecutive patients with objectively confirmed VTE between July 2015 and May 2017. Primary outcome was the proportion of patients identified at major risk of adverse events (bleeding or recurrent VTE). Secondary outcomes were rates of interventions, major or clinically relevant nonmajor bleeding (CRNMB), recurrent VTE, and all-cause mortality at 90 days. Among 304 participants, 5% (n = 15) were identified to be at major and 9% (n = 28) at possible risk for adverse events. Appropriate interventions to prevent harm were required in 40 patients. Rates of major bleeding, CRNMB, recurrence, and all-cause mortality were 0.3% (95% confidence interval [CI]: 0.1–1.8), 7.2% (95% CI: 4.8–10.7), 1.0 (95% CI: 0.3–2.9), and 1.6% (95% CI: 0.7–3.8), respectively. In conclusion, following discharge of acute VTE patients, a nurse-led pathway identified one in seven (14%) patients at major or possible risk of adverse events. Preemptive interventions to reduce harm translated into the low rates of bleeding and recurrence. The authors' experience highlights the feasibility and importance of a structured clinical surveillance pathway for acute VTE patients initiating NOAC therapy.

show abstract

“…5 Thus, we have conducted an observational study of screening practices after acute intermediate or high risk PE on a prospective cohort of venous thromboembolism (VTE), the REMOTEV registry. 6 Since November 2013, the Vascular Medicine Unit of Strasbourg University Hospital prospectively includes all consecutive patients hospitalized for acute VTE in the ongoing observational registry REMOTEV with a 1-year follow-up. 6 For the purpose of this publication, we analyzed data for all patients presenting with intermediate or high risk PE included from November 2013 to January 2016.…”

mentioning

confidence: 99%

“…6 Since November 2013, the Vascular Medicine Unit of Strasbourg University Hospital prospectively includes all consecutive patients hospitalized for acute VTE in the ongoing observational registry REMOTEV with a 1-year follow-up. 6 For the purpose of this publication, we analyzed data for all patients presenting with intermediate or high risk PE included from November 2013 to January 2016. All outcomes (death, recurrent VTE and bleeding) and new or persistent dyspnea occurring during the first 12 months following PE diagnosis were prospectively recorded.…”

mentioning

confidence: 99%

Real‐life practices of chronic thromboembolic pulmonary hypertension screening: Results from the REMOTEV observational study

Cordeanu

Younes

Canuet

et al. 2018

Clinical Respiratory J

Self Cite

View full text Add to dashboard Cite

Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes

Cited by 44 publications

References 26 publications

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study

Real‐life practices of chronic thromboembolic pulmonary hypertension screening: Results from the REMOTEV observational study

Contact Info

Product

Resources

About